After successfully becoming the first company to develop proprietary knowledge to control the production of cannabis cells in liquid media, BioHarvest Sciences (CSE:BHSC) CEO Ilan Sobel shares his thoughts on how the company is embarking on a journey to take a space in the cannabis market while making a fundamental difference to the overall health and wellness of the populations of the world.
“Our number one focus every day has to be around driving human utility value, how we make the world better every single day for the consumers through the use of our products,” Ilan said.
BioHarvest’s ground-breaking milestone leverages its patented BioFarming technology, independent of any specific cannabis strain genetics. This optimization of the trichome’s growth is a key condition and major enabler for the consistent, cost-efficient and sustainable production of plant-cell-based cannabis and cannabinoids.
The company takes pride in its breakthrough biotech technology, which allows it to deliver on the health and wellness needs of consumers and acquire that strong market momentum in 2021.
For more from Ilan Sobel, watch the full interview above.
Disclaimer: This interview is sponsored by BioHarvest Sciences (CSE:BHSC). This interview provides information which was sourced by the Investing News Network (INN) and approved by BioHarvest Sciences in order to help investors learn more about the company. BioHarvest Sciences is a client of INN. The company’s campaign fees pay for INN to create and update this interview.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with BioHarvest Sciences and seek advice from a qualified investment advisor.
This interview may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, receipt of property titles, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The issuer relies upon litigation protection for forward-looking statements. Investing in companies comes with uncertainties as market values can fluctuate.